Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Src I1

Inhibitor of Src kinase and p56lck tyrosine kinase
 
BML-EI398-0025 25 mg 328.00 USD
Do you need bulk/larger quantities?
 
Potent, dual site (ATP domain and substrate-binding domain) Src and Lck kinase inhibitor (IC50=44 and 88nM respectively). VEGFR2 IC50=0.32μM; c-fms IC50=30μM.

Product Specification

Alternative Name:6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine
 
Formula:C22H19N3O3
 
MW:373.4
 
CAS:179248-59-0
 
Purity:≥98% (HPLC)
 
Appearance:Off-white solid.
 
Solubility:Soluble in DMSO (5mg/ml).
 
Shipping:Ambient
 
Long Term Storage:Ambient
 
Use/Stability:Store, as supplied, at room temperature for up to 1 year. Store solutions at -20°C for up to 3 months.
 
Regulatory Status:RUO - Research Use Only
 
bml-ei398
Please mouse over
bml-ei398

Product Literature References

c-Src tyrosine kinase mediates high glucose-induced endothelin-1 expression: S.A. Manea, et al.; Int. J. Biochem. Cell Biol. 75, 123 (2016), Application(s): Cell culture, Abstract;
The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007), Abstract;
Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines: G. Tian, et al.; Biochemistry 40, 7084 (2001), Abstract;

Related Literature

Brochures
Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2020 Enzo Life Sciences, Inc.,